Items with tag "immunology"

News

The Nobel Assembly at Karolinska Institutet awards the 2018 Nobel Prize in Physiology or Medicine jointly to James P. Allison and Tasuku Honjo

1st October 2018 Cancer kills millions of people every year and is one of humanity’s greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor cells …

Read more

Strategic Ablynx - Sanofi collaboration for up to 8 Nanobodies in immunology and inflammation

Ablynx announced that it has entered into a research collaboration and global exclusive licensing agreement with Sanofi initially focused on developing and commercialising Nanobody®-based therapeu…

Read more

argenx and Broteio Pharma jointly develop antibodies for severe autoimmune diseases

argenx announces its new collaboration with Broteio Pharma. Broteio will perform preclinical research using argenx' SIMPLE antibody platform after which argenx has the exclusive option to license …

Read more

Merck releases compelling data on Ablynx-developed psoriasis nanobody

Data from a phase Ib study reveal the Ablynx-developed bi-specific nanobody targeted against IL-17A/F as a promising new therapy to treat psoriasis. Patients in the highest dose group achieved 90%…

Read more

MERCK REPORTS ENCOURAGING RESULTS WITH ABLYNX' PSORIASIS NANOBODY

• Primary objective of safety and tolerability met • In the three highest dose groups, 100% of patients achieved a 75% or greater reduction in disease activity compared to 0% for placebo • The…

Read more

Protein found that drives allergic sensitivity in newborns

Scientists from the lab of Bart Lambrecht (VIB-UGent) and Erasmus University have found evidence that interleukin-33 (IL-33), a protein created by white blood cells, is a key driver of allergic se…

Read more

New insights in genetic defect allow prevention of fatal illnesses in children

A team of scientists led by prof. Adrian Liston (VIB–KU Leuven) and prof. Isabelle Meyts (UZ Leuven – KU Leuven) were able to characterize a new genetic immunodeficiency resulting from a mutation …

Read more

argenx launches Phase II study of ARGX-113 for the treatment of myasthenia gravis

Llama antibody engineer argenx today announced the initiation of a Phase II proof-of-concept study of ARGX-113 in patients with myasthenia gravis (MG). "MG is a rare and debilitating muscle d…

Read more

23,5 million euro for a cutting-edge allergy treatment

ASIT Biotech, a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, anno…

Read more

Gene therapy play Orchard raises 30.7 million

Orchard Therapeutics (London, U.K.) raised $30.7 million in a series A round to develop ex vivo autologous hematopoietic stem cell gene therapies for primary immune deficiencies, metabolic disease…

Read more

Galapagos finally managed to close long awaited deal

Earlier this year, AbbVie turned down its deal with Galapagos for co-development and commercializiation of the drug filgotinib for treatment of reumathoid arthritis. Last week, Galapagos announced…

Read more

Galapagos' drug also active against Crohn's disease!

Galapagos has been working for a while on a drug, called Filgotinib, against rheumatoid arthritis. But this drug candidate also appears to have other therapeutic properties. Galapagos is now evalu…

Read more

New VIB-UHasselt research group to tackle MS

VIB and UHasselt have teamed up for the creation of a new research group. After an international selection procedure, renowned German professor Markus Kleinewietfeld was appointed to lead the newl…

Read more

Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an investor in Wales. It concerns the Wales Life Scienc…

Read more

Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary rights of GLPG1205 and GLPG1690, two molecules under…

Read more

Insights

Saving lives through fundamental research: James Allison wins Dr. Paul Janssen Award 2018

Saving lives through fundamental research: James Allison wins Dr. Paul Janssen Award 2018

Dr. James Allison has dedicated his career to improving our fundamental understanding of how the adaptive immune system works. Much of what you will find on T cells in today’s immunology textbooks…

Read more

Uncovering the secrets of inflammasomes

Uncovering the secrets of inflammasomes

Mohamed (Mo) Lamkanfi made the jump from academia to industry a mere eight months ago, to pursue a career with the Janssen Pharmaceutical Companies of Johnson & Johnson, as Head, Innate Immunity, …

Read more

Damya Laoui at the forefront of cancer immunotherapy

Damya Laoui at the forefront of cancer immunotherapy

Photo copyright: VUB / Thierry Geenen Last year, Damya Laoui received the prestigious American MIT-prize for young innovators under 35 for her research on cancer immunotherapy.  She is current…

Read more

Leveraging terabytes of single cell data

Leveraging terabytes of single cell data

Yvan Saeys is a young professor at VIB-UGent. As the group leader of the department of Data Mining and Modeling for Biomedicine he focuses on developing computational models for single cell analys…

Read more

UCB psoriasis drug approved for use in mothers

UCB psoriasis drug approved for use in mothers

The UCB core drug CIMZIA® has just been approved by European Medicines Agency (EMA) for use in pregnant and breastfeeding mothers. The company has also sought to have CIMZIA approved for psoriasis…

Read more

Dendritic cells boosted with mRNA form promising cancer immunotherapy

Dendritic cells boosted with mRNA form promising cancer immunotherapy

With its expertise in mRNA production and knowledge of the biology of dendritic cells, eTheRNA has developed TriMix, a new mRNA technology platform. TriMix consists of a cocktail of three mRNAs, w…

Read more

Lars Klareskog pushes rheumatology beyond symptomatic treatment

Lars Klareskog pushes rheumatology beyond symptomatic treatment

Over the years, the perception of inflammatory diseases has changed drastically. The advent of cytokine inhibitors meant great improvement to many patients, especially those suffering from rheumat…

Read more

Macrophages to protect you from asthma

Macrophages to protect you from asthma

It has long been known that exposure to microbes can play a protective role against the subsequent development of asthma. Researchers from GIGA of the University of Liège provide an explanation an…

Read more

The choroid plexus: where inflammation meets neurology

The choroid plexus: where inflammation meets neurology

We write about change — about impact and consequences, about discoveries and the people behind them. This time, we introduce you to Roosmarijn Vandenbroucke, a discovery scientist at IRC-VIB and a…

Read more

Faeces transplant as treatment for Crohn's disease

Faeces transplant as treatment for Crohn's disease

Crohn’s disease is a complicated chronic disorder, the complexity of which has only become clear during the last decade. It has become increasingly evident that your food pattern and gut microbiot…

Read more

Growing up on a farm protects from asthma

Growing up on a farm protects from asthma

The research team at the Flanders Institute for Biotechnology (VIB) headed by Bart Lambrecht and Hamida Hammad has shown that children growing up on a farm are protected against asthma. They also …

Read more

Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related disease, causing abdominal pain, diarrhea, fever a…

Read more

The success of adipose stem cells

The success of adipose stem cells

Cell therapy specialist TiGenix has announced that their product for the treatment of complex perianal fistulas, Cx601, has met the primary endpoint of their European phase three clinical trial. T…

Read more

MS slowly but surely unravels its secrets

MS slowly but surely unravels its secrets

Piet Stinissen is Professor and Dean at the Faculty of Medicine and Life Sciences at the University of Hasselt, where he is head of the Immunology and Biochemistry laboratory. He is a biochemist a…

Read more

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

UGent XpandInnovation KU Leuven Biowin Itera Life Science GSK Janssen V-Bio Ventures Flanders.bio Turnstone

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.